Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody

Completed · Phase 1 · Has a placebo group

Conditions studied: Cytomegalovirus Infections

In brief

The purpose of this study is to compare the safety profile in healthy adult volunteers of single or multiple intravenous administrations of TCN-202 as compared with placebo.

Key facts

Study ID

NCT01594437

Run by

Theraclone Sciences, Inc.

People needed

48

Starts

2012-05-01

Expected to finish

2013-03-01

Last updated by the study team

2014-03-21

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult volunteers
• Normal lab tests

You may not qualify if…

• Prior treatment with monoclonal antibody

Where it is running

• SNBL Clinical Pharmacology Center — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.